Pard6a Antibody

What is PARD6A and why is it an important research target?

PARD6A (Partitioning defective 6 homolog alpha) is a critical component of the cellular polarity complex that regulates epithelial cell tight junction formation and maintenance. It belongs to the PAR6 family, which includes three mammalian isoforms (PARD6A, PARD6B, and PARD6G), each with tissue-specific expression patterns and distinct functional characteristics . PARD6A has emerged as an important research target due to its involvement in cellular migration, invasion, and epithelial-mesenchymal transition (EMT), particularly in cancer contexts. Recent studies have demonstrated its role in promoting metastasis in ovarian cancer, making it a valuable target for understanding cancer progression mechanisms .

What types of PARD6A antibodies are available for research applications?

Researchers can access several types of PARD6A antibodies with distinctive properties suited for different experimental applications:

• Rabbit polyclonal antibodies: These recognize multiple epitopes of PARD6A and are typically suitable for Western blot (WB) and immunohistochemistry (IHC) applications. These antibodies are often generated using recombinant full-length human PARD6A as the immunogen and are affinity-purified to >95% purity by SDS-PAGE .

• Mouse monoclonal antibodies: These recognize specific epitopes (e.g., amino acids 257-346 of human PARD6A) and provide higher specificity. They are validated for Western blotting, immunoprecipitation, immunofluorescence, and ELISA applications .

When selecting an antibody, researchers should consider the specific application requirements, species reactivity (human, mouse, rat), and the target domain of interest within the PARD6A protein.

How can I validate the specificity of a PARD6A antibody for my experiments?

Validating antibody specificity is critical for generating reliable research data. For PARD6A antibodies, consider these methodological approaches:

• Positive control validation: Use cell lines with known high endogenous PARD6A expression (e.g., SKOV3, A2780) compared with low-expression cell lines (e.g., HO8910, OVCAR8) or normal controls like HOSEpiC .

• Overexpression validation: Transfect cells with a PARD6A expression construct (e.g., pCDNA3-FLAG-PARD6A) and empty vector controls. Verify antibody specificity by detecting increased signal in transfected cells using both the PARD6A antibody and an anti-tag antibody (e.g., FLAG) .

• Knockdown validation: Use siRNA or shRNA targeting PARD6A and confirm reduced signal in Western blot or immunohistochemistry. The search results demonstrate successful knockdown validation using siPARD6A1 and siPARD6A2 .

• Cross-reactivity assessment: Test against other PAR6 family members (PARD6B, PARD6G) to ensure specificity for the alpha isoform, particularly important when studying tissues expressing multiple isoforms.

What are the optimal conditions for using PARD6A antibodies in Western blotting?

For optimal Western blot results with PARD6A antibodies, follow these methodological guidelines:

• Sample preparation: Prepare cell lysates from tissues or cultured cells using standard lysis buffers containing protease inhibitors. For PARD6A detection, include phosphatase inhibitors if examining phosphorylation status.

• Protein loading: Load 20-50 μg of total protein per lane. PARD6A has a molecular weight of approximately 37 kDa , so use appropriate percentage gels (10-12%) for optimal resolution.

• Blocking and antibody incubation:

  • Block membranes with 5% non-fat milk or BSA in TBST

  • For rabbit polyclonal antibodies, typically use 1:1000 dilution for primary antibody incubation

  • For mouse monoclonal antibodies, typically use 1:200 to 1:1000 dilution

  • Incubate with appropriate HRP-conjugated secondary antibodies

• Detection controls: Include positive controls (cells with known PARD6A expression) and loading controls (β-actin, GAPDH) to normalize expression levels.

• Expected results: PARD6A appears as a band at approximately 37 kDa. Verification can be performed using PARD6A-overexpressing cells or tagged constructs as reference standards .

How should PARD6A antibodies be optimized for immunohistochemistry applications?

For successful immunohistochemical detection of PARD6A in tissue samples:

• Tissue fixation and processing: Use 10% neutral-buffered formalin fixation and paraffin embedding. Optimal section thickness is 4-5 μm.

• Antigen retrieval: Heat-induced epitope retrieval in citrate buffer (pH 6.0) is typically effective for PARD6A antibodies.

• Blocking and antibody incubation:

  • Block endogenous peroxidase with 3% H₂O₂

  • Block non-specific binding with normal serum

  • Use optimized antibody dilution (typically 1:100 to 1:500 for commercial antibodies)

  • Incubate at 4°C overnight or at room temperature for 1-2 hours

• Detection system: Use appropriate detection systems based on the host species of your primary antibody (e.g., HRP-polymer systems).

• Evaluation methods: For PARD6A in clinical samples, evaluation using H-score or other semi-quantitative methods is recommended, particularly when assessing differences in expression between normal tissues and cancer samples of varying grades and stages .

• Controls: Include positive control tissues (ovarian cancer tissue for PARD6A) and negative controls (primary antibody omission).

What are effective approaches for detecting PARD6A in cellular localization studies?

PARD6A is known to localize at tight junctions and participate in polarity complexes. For optimal cellular localization studies:

• Immunofluorescence protocol:

  • Fix cells with 4% paraformaldehyde (10-15 minutes at room temperature)

  • Permeabilize with 0.1-0.5% Triton X-100

  • Block with 1-5% BSA or normal serum

  • Incubate with PARD6A primary antibody (typically 1:50 to 1:200 dilution)

  • Use fluorophore-conjugated secondary antibodies appropriate for the host species

• Co-localization studies: Co-stain with markers of:

  • Cell junctions (E-cadherin, ZO-1)

  • Polarity complex partners (aPKC, CDC42)

  • EMT markers (SNAIL1, VIMENTIN) for cancer studies

• Image acquisition: Use confocal microscopy for optimal resolution of subcellular localization, particularly at cell-cell junctions and polarized structures.

• Controls and validation: Include known localization controls and validate specificity with PARD6A knockdown or overexpression systems.

How can PARD6A antibodies be used to investigate protein-protein interactions within the polarity complex?

PARD6A functions within a complex network of protein interactions. To investigate these interactions:

• Co-immunoprecipitation (Co-IP):

  • Use PARD6A antibodies for immunoprecipitation (validated monoclonal antibodies are preferred)

  • Immunoblot for known interaction partners:

    • aPKC (interacts with the PB1 domain)

    • Cdc42 (interacts with the semi-CRIB domain)

    • Par3, Lgl, and other polarity proteins

  • For studying specific domain interactions, use mutant constructs (K19A mutation disrupts aPKC binding; ΔPro136 disrupts Cdc42 binding; M235W disrupts Lgl binding)

• Proximity ligation assay (PLA):

  • Enables in situ detection of protein interactions

  • Use pairs of antibodies against PARD6A and putative interaction partners

  • Particularly useful for detecting transient or context-dependent interactions

• Domain mapping:

  • Combine with expression constructs containing specific domain mutations

  • Validate disruption of interactions through functional assays

What methods can be used to study PARD6A's role in epithelial-mesenchymal transition (EMT) and cancer progression?

PARD6A has been implicated in EMT and cancer progression. To study these functions:

• Expression analysis in cancer tissues:

  • Use immunohistochemistry with PARD6A antibodies to assess expression in cancer tissues of different stages, grades, and metastatic status

  • Correlate expression with clinical parameters and EMT marker expression

• Functional studies with gene manipulation:

  • PARD6A knockdown using siRNA/shRNA approaches:

    • Demonstrated to suppress migration and invasion in ovarian cancer cell lines

    • Verify knockdown efficiency by Western blot with PARD6A antibodies

  • PARD6A overexpression:

    • Shown to promote migration and invasion in low-expressing cell lines

    • Confirm overexpression by Western blot

• EMT pathway analysis:

  • After PARD6A manipulation, assess changes in EMT markers:

    • E-cadherin (epithelial marker)

    • VIMENTIN (mesenchymal marker)

    • SNAIL1 (EMT transcription factor)

• In vivo metastasis models:

  • Use PARD6A-manipulated cells in xenograft models

  • Assess metastatic potential through lung nodule formation

  • Validate using H&E staining and immunohistochemistry with human-specific markers

How can I investigate the signaling pathways regulated by PARD6A using antibody-based approaches?

To study PARD6A-mediated signaling pathways:

• Pathway component analysis:

  • After PARD6A manipulation, use antibodies against key signaling molecules to assess:

    • Integrin β1 and ILK expression and activation

    • SNAIL1 expression and localization

    • Downstream targets like E-cadherin and VIMENTIN

• Phosphorylation status analysis:

  • Use phospho-specific antibodies to detect activation of signaling components:

    • aPKC phosphorylation status

    • ILK-mediated signaling

• Chromatin immunoprecipitation (ChIP):

  • Investigate transcriptional regulation mechanisms

  • Particularly useful for understanding how PARD6A-regulated pathways affect gene expression

  • Example: ILK has been shown to regulate SNAIL1 transcription

• Combine with pharmacological inhibitors:

  • Target specific nodes in the pathway

  • Use PARD6A antibodies to track changes in protein localization and complex formation

What are common challenges when using PARD6A antibodies and how can they be addressed?

Researchers may encounter several challenges when working with PARD6A antibodies:

• Cross-reactivity with other PAR6 family members:

  • Problem: PARD6A, PARD6B, and PARD6G share structural similarities

  • Solution: Verify antibody specificity using overexpression of specific isoforms and Western blot validation

  • Alternative approach: Use epitope-specific antibodies targeting unique regions of PARD6A

• Low endogenous expression levels:

  • Problem: PARD6A may be expressed at low levels in some cell types

  • Solution: Optimize protein loading amounts (50-100 μg may be needed)

  • Alternative: Use enrichment methods like immunoprecipitation before detection

• Non-specific bands in Western blot:

  • Problem: Additional bands may appear besides the expected 37 kDa band

  • Solution: Optimize blocking conditions and antibody dilutions

  • Validation: Use PARD6A knockdown samples to confirm which band represents the specific signal

• Variability in immunohistochemistry staining:

  • Problem: Inconsistent staining patterns across samples

  • Solution: Standardize fixation times, antigen retrieval conditions, and staining protocols

  • Control: Include positive control tissues with known PARD6A expression in each batch

How should I interpret contradictory results from different PARD6A antibodies?

When faced with discrepancies between results obtained with different PARD6A antibodies:

• Compare epitope recognition sites:

  • Different antibodies may target distinct domains of PARD6A

  • Domain-specific antibodies might yield different results if:

    • Protein interactions mask specific epitopes

    • Post-translational modifications affect epitope recognition

    • Protein conformation varies in different cellular contexts

• Validate with complementary approaches:

  • Combine antibody-based detection with mRNA analysis

  • Use tagged PARD6A constructs with antibodies against the tag

  • Implement PARD6A knockdown or knockout controls

• Consider context-dependent factors:

  • Cell type-specific PARD6A expression patterns

  • Changes in localization under different experimental conditions

  • Formation of different protein complexes that may mask epitopes

• Hierarchical validation strategy:

  • Start with Western blot validation of different antibodies

  • Progress to cellular assays with validated antibodies

  • Correlate findings with functional outcomes in manipulated systems

How can I quantitatively analyze PARD6A expression in tissue samples for correlation with clinical parameters?

For rigorous quantitative analysis of PARD6A in clinical samples:

• Immunohistochemistry scoring methods:

  • H-score: Combines intensity (0-3) and percentage of positive cells

  • Allred score: Combines proportion and intensity scores

  • Digital image analysis: Use software for automated quantification

• Statistical approaches for clinical correlations:

  • Stratify samples by PARD6A expression levels (high vs. low)

  • Correlate with clinical parameters:

    • Tumor stage (e.g., stages I-II vs. III-IV)

    • Differentiation status (well, moderate, poor)

    • Presence of lymphatic metastasis

• Multivariate analysis:

  • Include PARD6A expression alongside other biomarkers

  • Control for confounding variables

  • Assess independent prognostic value

• Survival analysis methods:

  • Kaplan-Meier curves stratified by PARD6A expression

  • Cox proportional hazards models

  • Time-dependent ROC analysis for predictive value assessment

How might PARD6A antibodies be used in multi-parameter analysis of polarity complex dynamics?

Advanced multi-parameter techniques offer new opportunities for studying PARD6A:

• Multiplexed immunofluorescence approaches:

  • Simultaneous detection of multiple polarity complex components

  • Analysis of co-localization patterns in different cellular contexts

  • Tyramide signal amplification methods for detection of low-abundance proteins

• Mass cytometry (CyTOF) applications:

  • Metal-conjugated antibodies for high-dimensional analysis

  • Simultaneous detection of PARD6A with dozens of other markers

  • Single-cell resolution for heterogeneity analysis

• Live-cell imaging strategies:

  • Combine with fluorescently-tagged constructs

  • Track dynamic changes in PARD6A localization during polarity establishment

  • FRET/FLIM approaches to study protein-protein interactions in real-time

• Spatial transcriptomics integration:

  • Correlate PARD6A protein localization with spatial gene expression patterns

  • Identify neighborhood-specific signaling networks

What emerging technologies might enhance the specificity and sensitivity of PARD6A detection in research applications?

Emerging technologies are improving antibody-based detection:

• Nanobody and single-domain antibody approaches:

  • Smaller size enables better tissue penetration

  • Potential for improved access to sterically hindered epitopes in protein complexes

  • Enhanced specificity for particular conformational states

• Protein-fragment complementation assays:

  • Split reporter proteins fused to PARD6A and interaction partners

  • Direct visualization of protein-protein interactions

  • Quantitative assessment of interaction dynamics

• Proximity labeling methods:

  • APEX2 or BioID fused to PARD6A

  • Identification of novel proximity partners in specific cellular contexts

  • Temporal control of labeling for capturing dynamic interactions

• Super-resolution microscopy applications:

  • Nanoscale visualization of PARD6A distribution

  • Co-localization analysis at sub-diffraction resolution

  • Combination with expansion microscopy for enhanced spatial resolution